SINGLE-CENTER OBSERVATIONAL STUDY OF SEIZURE TYPES IN RARE GENETIC EPILEPSIES
The purpose of this research study is to better describe specific movements that are seizures in rare genetic epilepsies (which may be different than other more common epilepsy syndromes). This can help parents and doctors perform seizure counts more accurately. This will help individual patients and doctors with medication management and evaluate how well patients are doing over time. On a larger scale, this study can also help specific rare genetic epilepsy syndromes when there is a genetic or drug trial to ensure accurate seizure counting is being performed, and to better determine if an intervention is truly helping with seizures.
Single-Center Pilot Study of Living Donor Kidney Transplant from HIV-positive Donor to HIV-positive Recipient
This study will evaluate the feasibility and safety of living donor kidney transplant from an HIV-infected donor to an HIV-infected recipient.
Single-center study of pupillary dilation during post-auricular vagal nerve stimulation
We will evaluate pupillary dilation from vagal nerve stimulation of Arnold’s Nerve, a branch of the vagus nerve, during routine cochlear implantation surgery. Vagal nerve stimulation has the potential to improve performance on cognitive tasks.
Sinonasal Cancer | NYU Langone Health
Doctors at Perlmutter Cancer Center manage sinonasal cancer with surgery, radiation therapy, and chemotherapy.
Sinonasal Disorder Services for Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone create child-centered care plans to manage disorders affecting the nose and sinus.
Site for A Multi-Center Prospective Randomized Controlled Trial Comparing the Safety and Effectiveness of prodisc C SK and prodisc C Vivo to Mobi-C Cervical Disc in the Treatment of Two-Level Symptomatic Cervical Disc Disease (SCDD)
Research study to evaluate the safety and effectiveness of prodisc C SK and prodisc C Vivo versus Mobi-C (currently available on market).
Site for A RANDOMIZED DOUBLE-BLIND MULTI-CENTER COMPARATIVE EFFECTIVENESS STUDY OF SPIRONOLACTONE VERSUS DOXYCYCLINE HYCLATE FOR THE TREATMENT OF ACNE IN WOMEN
Site for To determine whether spironolactone is non-inferior to the oral tetracycline-class antibiotic doxycycline hyclate in the treatment of acne in women
Site for AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Site for This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Site for Abaloparatide versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial
Site for This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men = 50 years of age with acute fractures of the pelvis. We will extend this study with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention.Our primary outcome is CT evidence of fracture healing at the 12-week endpoint. After initiating ABALOPARATIDE or ABALOPARATIDE placebo, all patients will get follow-up pelvic radiographs following standard care and radiographs will stop when healing occurs.
Site for AN INTERVENTIONAL MULTI-CENTER INVESTIGATION OF SINGLE LEVEL TRANSFORAMINAL LUMBAR INTERBODY FUSION (TLIF) STABILIZED WITH PEDICLE SCREWS
Site for An interventional, multi-center (up to 15), prospective, non-blinded investigation of single-level TLIF stabilized with pedicle screws. The purpose is to intend to treat the study population by demonstrating clinical success (safety and efficacy) of the TLIF instrumented with pedicle screws with respect to composite endpoints.